| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f478a59c2aa84b2e13aecfcf71233a4f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate |
2018-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f22ce9b4c4ce6309c24782c60275eda
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f16a11cb21b404a1df3e87df1fe6bdba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_136f1aeb9a2e8d5be66ca17c5e59e3ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4f06a5b6eab48bf8f83c5ed99166885
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60292d421cf5e531e77ed6e12865e8d2 |
| publicationDate |
2018-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2018203300-A1 |
| titleOfInvention |
Insulinotropic peptide derivative with modified N-terminal charge |
| abstract |
The present invention relates to an insulinotropic peptide derivative with a modified N-terminal charge and a pharmaceutical composition including the same. Specifically, 5 the insulinotropic peptide derivative is characterized in that the N-terminal positive charge of the insulinotropic peptide is modified to a neutral or net negative charge at neutral pH. The insulinotropic peptide derivative according to the present invention is rapidly dissociated from the 10 GLP-1 receptor owing to the above modification in the N terminal charge, and exhibits enhanced insulinotropic ability and blood glucose-lowering activity compared to the native insulinotropic peptide while maintaining its stability in blood. Accordingly, the insulinotropic peptide 15 derivative of the present invention is very useful for the treatment of type 2 diabetes. - 45 - |
| priorityDate |
2013-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |